CClinicalTrials.gg
CompletedNCT03358524Updated Mar 2, 2018

Effects of Vitamin E Supplementation on Free Radicals and Fat Level of Obese Adolescence in Jakarta, Indonesia

A Phase 4 interventional study of Vitamin E 400 UNT and Placebo oral capsule in Obesity, Adolescent and Oxidative Stress, sponsored by Indonesia University. Completed at 1 site in Indonesia. Open to participants aged 14 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-02.

Sponsored by Indonesia University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
14 Years to 18 Years
Sex
All
01

Study summary

This study evaluate supplementation of vitamin E (alpha-tocopherol) in obese adolescent. Half of the patient will receive vitamin E and the other half received placebo

Read the detailed description

One of obesity treatments that play important role is antioxidant diet. The effects of vitamin E supplementation as an antioxidant treatment in obese adolescent have not been concluded yet in Indonesia. The primary aim of this study is to observe oxidative stress biomarker (isoprostane) in obese teenagers who consume vitamin E for 2 months. The secondary aim is to observe their body mass index and lipid profile after supplementation

The study is randomized, double blind, placebo controlled trial in design and employed a consecutive sampling technique to sample subjects of 70 obese adolescent age 14 - 18 in senior high schools Jakarta.

Blood tests of lipid profile (total cholesterol, HDL, LDL, Triglyceride), fasting blood glucose, liver function (AST,ALT) and oxidative stress biomarker (isoprostane) were taken for every subject after done fasting for 12 hours.

This study is a randomized allocation and double blind technique. subjects divided into two groups, which one group receiving treatment of vitamin E and other group receiving placebo.

The dose and duration of vitamin E treatment is 400 IU per day for 2 months. At the end of treatment, all subjects had to run the same medical interview, physical examination and blood test.

02

Conditions studied

  • Obesity, Adolescent
  • Oxidative Stress

Browse trials for

03

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Obesity BMI ≥ p95 (CDC growth curve)

Exclusion criteria

Exclusion Criteria:

  • Consuming antioxidants drug regularly within recruiting time
  • Consuming Orlistat
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Vitamin E 400 IU

    Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks

    Drug: Vitamin E 400 UNT

  • Placebo comparator
    Placebo

    Placebo capsule once per day orally for 8 weeks

    Drug: Placebo oral capsule

Interventions

  • DrugVitamin E 400 UNT

    Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)

    Also known as: Vitamin E

  • DrugPlacebo oral capsule

    sugar capsule manufactured to mimic vitamin E capsule once per day

    Also known as: Placebo

05

What researchers measure

Primary outcomes

  1. Isoprostane (oxidative stress)

    pg/ml

    Time frame: 8 weeks

Secondary outcomes

  1. Total Cholesterol

    mg/dl

    Time frame: 8 weeks

  2. LDL Cholesterol

    mg/dl

    Time frame: 8 weeks

  3. HDL Cholesterol

    mg/dl

    Time frame: 8 weeks

  4. Triglycerides

    mg/dl

    Time frame: 8 weeks

  5. Body weight

    kilograms

    Time frame: 8 weeks

  6. Body Height

    centimeters

    Time frame: 8 weeks

  7. BMI

    kg/m\^2

    Time frame: 8 weeks

06

Study locations

1 site
  • SMA Labschool
    Jakarta, 13220, Indonesia
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03358524
Lead sponsor
Indonesia University
Responsible party
Ali Alhadar (Pediatric Fellowship at Pediatric Nutrition and Metabolic disease, Indonesia University) — Principal investigator
First posted
Nov 30, 2017
Start date
Sep 28, 2017
Primary completion
Feb 20, 2018
Completion
Mar 1, 2018
Last update
Mar 2, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion